Eupraxia Pharmaceuticals (EPRX) Company Cash on Hand

Eupraxia Pharmaceuticals - graphic logo of issuer EPRX

Eupraxia Pharmaceuticals (EPRX) minimizes operational risks by developing extended-release drug delivery systems for oncology and arthritis. Management is currently actively adapting these technologies to meet final clinical trial requirements. High physician confidence is based on the innovative drug delivery method. The current cash position demonstrates financial stability, while 0.13 determines the current value of this metric.

EPRX - Eupraxia Pharmaceuticals Company Liquid Assets over the range 04/06/2024 - 11/21/2026

Financial and market metric breakdowns for eupraxiapharma.com (EPRX)

Fundamental company valuation:Eupraxia Pharmaceuticals
Product sample of Eupraxia Pharmaceuticals

For a fundamental valuation of Eupraxia Pharmaceuticals (EPRX), analyzing its financial stability amidst innovation development is critical. This metric measures the volume of liquid assets, determining the business's ability to cover operating expenses in the absence of revenue. By examining the history of cash reserves, an investor can assess the capital burn rate. This ensures the uninterrupted development of the long-acting drug ecosystem for arthritis therapy until the point of commercialization.

Direct competitors

Company Cash Funds Haleon (HLN)|Company Cash Volume Kenvue Inc. (KVUE)|Company Cash Volume VRNA (veronapharma.com)|Company Cash Balance MENS|LGND: Company Cash on Hand|Company Cash Balance AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Company Cash on Hand|Alvotech - Company Cash Balance|Company Cash on Hand LQDA|Galapagos Genomics (GLPG) - Company Liquid Assets|Company Cash Volume ANIP|Company Cash on Hand Afrezza MNKD|Company Cash Funds Amphastar AMPH|Company Liquid Assets Pacira BioSciences (PCRX)|ARS Corp - Company Cash Volume|TBPH: Company Cash Funds|AQST: Company Cash Volume|SCPH - Company Liquid Assets|TECX (Tectonic) - Company Cash Volume|Company Cash Reserve Tonix Pharmaceuticals Holding Corp. TNXP|Company Cash Funds SXT Pharmaceuticals (SXTC)|BHST - Company Cash Reserve|eXoZymes - Company Cash on Hand|Company Cash Volume oramed.com ORMP|ENTX - Company Cash Funds|Company Liquid Assets MindWalk Holdings HYFT|ABVC: Company Cash Volume|Company Cash on Hand Cumberland Pharmaceuticals Inc.|Company Cash Funds Quantum BioPharma Limited|FGEN: Company Cash Balance|Company Cash Volume TELO|Rani Therapeutics Holdings, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Synergy CHC Corp. SNYR|Company Cash Balance RLYB|LEXX: Company Cash on Hand|Company Cash Balance PULM (Pulmatrix Corporation)|Pheton Holdings Limited (PTHL) - Company Cash Funds|Company Cash on Hand Aptorum|Company Cash on Hand LYRA|Impact BioMedical Inc - Company Total Cash Volume|Company Cash Volume TNFA|YCBD - Company Cash Reserve|PainReform Ltd. - Company Cash on Hand|CYTO (Auris Medical) - Company Total Cash Volume|LIPO - Company Cash Funds|Company Cash Balance OPTN (OptiNose)|PIRS: Company Cash Volume|Procaps Group S.A. (PROC) - Company Cash Volume|PTPI (Petros Pharma) - Company Cash Volume|QLI: Company Cash Balance|Company Cash Volume SLRN|TFFP (TFF Pharmaceuticals Inc.) - Company Cash Balance